Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +17.95%
#2 clBTC clBTC +12.15%
#3 OpenEden OpenEden +11.48%
#4 BasedHype BasedHype +11.14%
#5 Wrapped Ether (Mantle Bridge) Wrapped Ether (Mantle Bridge) +8.73%
#6 Not in Employment, Education, or Training Not in Employment, Education, or Training +8.41%
#7 Mantle Staked Ether Mantle Staked Ether +8.34%
#8 Mantle Restaked ETH Mantle Restaked ETH +8.01%
#9 MarsCoin MarsCoin +6.65%
#10 EfficientFrontier EfficientFrontier +4.93%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
Cyxone AB (publ) Cyxone AB (publ)

Cyxone AB (publ)

CYXO
Peringkat dalam Saham #40403
Cyxone AB (publ) is a clinical-stage biotechnology firm focused on developing... Cyxone AB (publ) is a clinical-stage biotechnology firm focused on developing innovative, disease-modifying therapies. Its primary therapeutic targets include rheumatoid arthritis, multiple sclerosis, and acute respiratory illnesses caused by viruses. The company's pipeline features Rabeximod, currently in Phase II clinical trials for both rheumatoid arthritis and COVID-19. Additionally, T20K, a drug candidate for multiple sclerosis, is undergoing Phase 1 evaluation. Established in 2015, the company is headquartered in Malmö, Sweden.
Harga Saham
$0.00162013
Terakhir disinkronkan: 2025-01-03
Kapitalisasi Pasar
$156.25K
Perubahan (1 hari)
0.36%
Perubahan (1 tahun)
0.00%
Negara
SE
Perdagangan Cyxone AB (publ) (CYXO)

Kategori

Healthcare
Laba untuk Cyxone AB (publ) (CYXO)
Laba pada Jun 2024 TTM: $-2.04M
Menurut laporan keuangan terbaru dari Cyxone AB (publ), laba saat ini perusahaan adalah $-2.04M. Pada tahun 2022, perusahaan memperoleh laba sebesar $-4.07M, peningkatan dibandingkan laba tahun 2021 sebesar $-4.98M. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk Cyxone AB (publ) dari 2015 hingga 2026
Laba pada akhir setiap tahun
Tahun Laba Mengubah
2026 (TTM) $-2.04M -10.32%
2023 $-2.28M -44.05%
2022 $-4.07M -18.14%
2021 $-4.98M -16.09%
2020 $-5.93M 57.40%
2019 $-3.77M 118.05%
2018 $-1.73M 60.09%
2017 $-1.08M 135.58%
2016 $-458.07K -2,484.88%
2015 $19.21K 0.00%
Laba untuk perusahaan serupa atau pesaing
Perusahaan Laba Perbedaan Laba Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -258,252.37%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -95,564.36%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -147,199.10%
BE